



This is a repository copy of *CFHealthHub: Complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/119740/>

Version: Accepted Version

Proceedings Paper:

Hind, D., Maguire, C., Cantrill, H.R. et al. (2 more authors) (2017) CFHealthHub: Complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial. In: Journal of Cystic Fibrosis. European Cystic Fibrosis Conference, 7–10 June 2017, Seville, Spain. Elsevier , S40-S41.

[https://doi.org/10.1016/S1569-1993\(17\)30291-6](https://doi.org/10.1016/S1569-1993(17)30291-6)

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

CFHealthHub: Complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial

D. Hind¹, C. Maguire¹, H. Cantrill¹, A. O'Cathain², M. Wildman³, for the CFHealthHub group

¹University of Sheffield, Sheffield Clinical Trials Research Unit, Sheffield, United Kingdom, ²University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, United Kingdom, ³Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

Objectives:

Test processes for / feasibility of a full-scale RCT evaluating CFHealthHub (CFHH) a theory-based complex intervention; test the acceptability of CFHH.

Methods:

Design: Non-blinded, pilot, parallel-group RCT (ISRCTN13076797).

Participants: People with CF at two units. Eligible: aged 16+; on UK registry; willing to take inhaled mucolytics and antibiotics via a chipped nebuliser. Those post lung transplant or on the active lung transplant list, unable to give informed consent or using dry powder inhalers are excluded.

Interventions: (1) collection / feedback of adherence data via chipped nebuliser and software platform, with strategies to empower self-management delivered online and in six face-to-face meetings over 5m with trained interventionists (n=32); (2) usual care (n=32).

Primary outcome: Feasibility of RCT defined as: (1) recruitment of >48 participants (75% of target) in four months; (2) valid primary outcome data for >85% of those randomised. Key clinical outcome: number of pulmonary exacerbations in a five-month period (Fuchs criteria).

Randomisation: 1:1 allocation via centralised web-based randomisation system, stratified by centre and days on intravenous antibiotics in previous year

Results:

Between 13/06/16 and 30/09/16, 64 participants were randomised to CFHH (n=31) or control (n=33) mean rate 4 per week. One unexpected serious adverse event was unrelated to CFHH. Retention rates, intervention acceptability and process data will be available by 31/03/2017.

Conclusion:

Recruitment to a full-scale trial is feasible.